Abstract Number: 1224 • 2019 ACR/ARP Annual Meeting
AR882, a Potent and Selective URAT1 Inhibitor with a Favorable Pharmacological, Pharmacokinetic and Toxicity Profile
Background/Purpose: AR882 is a potent and selective inhibitor of uric acid transporter 1 (URAT1), which is responsible for a majority of reabsorption of filtered uric…Abstract Number: 1225 • 2019 ACR/ARP Annual Meeting
Limits of Detection of Monosodium Urate Crystals in Synovial Fluid by Ultrasound
Background/Purpose: To evaluate limits of detection of ultrasound to detect monosodium urate crystals suspended in synovial fluid.Methods: Serial dilutions were made mixing liquid tophus aspirated…Abstract Number: 1226 • 2019 ACR/ARP Annual Meeting
Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity
Background/Purpose: Neutrophils are key immune cells participating in host defense through several mechanisms, including the formation of neutrophil extracellular traps (NETs). Excessive neutrophil activation has…Abstract Number: 1227 • 2019 ACR/ARP Annual Meeting
A Neutrophil Signature Is Strongly Associated with Cardiovascular Risk in Gout
Background/Purpose: Patients with gout have an increased cardiovascular morbidity and mortality, not fully explained by traditional cardiovascular risk factors. Xanthine oxidase-induced oxidative stress, increased lipid…Abstract Number: 1228 • 2019 ACR/ARP Annual Meeting
Soluble Triggering Receptor Expressed on Myeloid cells-1 (sTREM-1) Ameliorates Monosodium Urate Crystals (MSUC)-induced Inflammation in a Mouse Air-pouch Model of Gout
Background/Purpose: Myeloid cells membrane-bound TREM-1 (mTREM-1) amplifies toll like receptor (TLR)-4-mediated myeloid cells activation, accompanied by release of soluble TREM-1 (sTREM-1) that acts as a…Abstract Number: 1229 • 2019 ACR/ARP Annual Meeting
AR882, a Potent and Selective Uric Acid Lowering Agent Acting Through Inhibition of Uric Acid Reuptake, Shows Excellent Pharmacokinetics and Pharmacodynamics in a Phase 1 Clinical Trial
Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. A Phase 1…Abstract Number: 1230 • 2019 ACR/ARP Annual Meeting
Do Serum Urate-Associated Genetic Variants Influence Gout Risk in People on Diuretics? Analysis of the UK Biobank
Background/Purpose: Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) associated with serum urate and gout. An association between diuretic use and gout has also…Abstract Number: 1231 • 2019 ACR/ARP Annual Meeting
Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase
Background/Purpose: Hyperuricemia is associated with non-alcoholic fatty liver disease (NAFLD) (Yang C et al. PlosOne2017; 12:e0177249; Jaruvongvanich V et al. Eur J Gastroenterol Hepatol 2017;…Abstract Number: 1232 • 2019 ACR/ARP Annual Meeting
Whole Blood RNA Sequencing Study of Gout Cases and Controls Demonstrates Transcriptomic Differences with Relevance to Inflammatory Cell Activation
Background/Purpose: The transcriptomic changes accompanying the transition from asymptomatic hyperuricemia to gout are currently unknown but may be important for identifying and understanding important molecular…Abstract Number: 1233 • 2019 ACR/ARP Annual Meeting
Identification and Characterization of a Novel Dysfunction Variant p.I242T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…Abstract Number: 1234 • 2019 ACR/ARP Annual Meeting
Inconsistency in Uric Acid Reference Ranges Among 20 Top United States Hospitals: What Is “Normal”?
Background/Purpose: Elevated serum uric acid (UA) concentration is associated with the urate crystal deposition disorders gout and nephrolithiasis, as well as hypertension, the metabolic syndrome,…Abstract Number: 1235 • 2019 ACR/ARP Annual Meeting
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients
Background/Purpose: Gout is caused by the deposition of monosodium urate (MSU) crystals in joints due to chronic hyperuricemia. Long term treatment focuses on reducing sUA…Abstract Number: 1236 • 2019 ACR/ARP Annual Meeting
Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice
Background/Purpose: Pegloticase is an infused biologic for uncontrolled gout patients that is highly effective but can cause anti-drug antibodies that lead to a lack of…Abstract Number: 1237 • 2019 ACR/ARP Annual Meeting
Treatment with OLT1177™, an Oral NLRP3 Inflammasome Inhibitor, Reduces Systemic Inflammation During Gout Flares in Humans
Background/Purpose: Gout flares are characteristically mediated by the pro-inflammatory cytokine interleukin (IL)-1β. Uptake of monosodium urate (MSU) crystals by macrophages activates the nucleotide-binding domain and…Abstract Number: 1238 • 2019 ACR/ARP Annual Meeting
Monosodium Urate and Calcium Pyrophosphatecrystal-induced Interleukin 1 Production Depends on Glucose Uptake Through Glut1 Transporter
Background/Purpose: Monosodium urate (MSU) andmonoclinic calcium pyrophosphate dihydrated(mCPPD)crystals are responsible for relapsing acute arthritis which is driven by interleukin 1β (IL-1β).IL-1βproductionrelies onNLRP3 inflammasome activationleading to…
- « Previous Page
- 1
- …
- 838
- 839
- 840
- 841
- 842
- …
- 2425
- Next Page »